Cancer Diagnostics Global Market-Forecast of 2026

Publishing Date : June, 2020
Report Code : HCMD0171
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

The understanding of the pathways of cancer development and their causes has led to the development of novel methodologies, and there is an emerging trend towards precision health in today’s world to enhance cancer diagnosis, treatment, prevention and monitoring by using innovative diagnostic technologies with broader range.

Over the past few years technical advancements has led to the progression in cancer screening and treatment. The rise in number of new cases necessitates for more improvised technologies in diagnosis and monitoring of cancer. Cancer diagnostics are the foundation for the successful cancer prevention, where it provides quantitative measurements, changes at the genetic level thereby finding the underlying mechanism of disease and enabling the oncologist to tailor care at individual level and facilitating the personalized medicine practice.

Due to the side effects of radiation and other image-based diagnosis of cancer, there is a huge opportunity for non-image based techniques such as in-vitro diagnostics comprising tests based on molecular biology and immunology. These tests provide rapid and precise information about cancer and have revolutionized cancer management around the world. Some of the advantages of non-image based diagnostics are, up to 70% of the healthcare decisions are influenced by molecular and immune-based tests further improving the quality of personalized care of the patient, potential improvement in the patient outcome and facilitate early detection of cancer with sensitive assays thereby reducing the cost of healthcare of an individual.

According to IQ4I analysis, the cancer diagnostics global market is expected to reach $10,627.4 million by 2026 growing at a high single digit CAGR from 2019 to 2026. The growth of cancer diagnostic market is driven by the increasing number of cancer associated with the lifestyle, dramatic changes in the demography, advances in the disease genomics, also adoption of nationwide cancer screening programs as a part of national cancer control plans by individual countries (almost 120 countries have included national plans for cervical and breast cancer screening programs respectively) and discovery of new drugs. Cancer diagnostic tests have provided a greater value and are likely to play an escalating role in the future market.

The commercialization of cancer diagnostics techniques depends on economical, clinical and logistic challenges. One among them is the reimbursement system with suitable coding, positive coverage, and assessment of the price of novel diagnostics. With the reimbursement policies, all patients can access all new diagnostic tests on sustained bases thereby reducing the financial pressure. Also, high investment by major players for the production and release of new diagnostics techniques to the market will have a major role in driving the cancer diagnostics market. The restraints of the cancer diagnostics will include lack of skilled professionals, high cost of advanced techniques, product recall due to manufacturing defects and quality issues, stringent and time consumption for getting approvals from the regulatory bodies, lack of reimbursement will also hamper the growth of cancer diagnostic market.

The cancer diagnostics global market is segmented based on technology, sample source, application and end-users. The technology market is further categorized into immunoassays, molecular-based assays and others. The immunoassays global market is further sub-segmented into Immunohistochemistry (IHC), Enzyme Linked Immunosorbent Assay (ELISA) and others comprising of RIA (Radioimmunoassay), CLIA (Chemiluminescence), and FIA (Fluorescence immunoassays), among which, ELISA commanded the largest revenue in 2019, and IHC is expected to grow at a strong double digit CAGR from 2019 to 2026. The molecular-based global market is further sub-segmented into in-situ hybridization, PCR, microarray and sequencing, among which PCR commanded the largest revenue in 2019, the sequencing segment is expected to grow at a strong double digit CAGR from 2019 to 2026. The other technology segment is expected to grow at a mid single digit CAGR from 2019 to 2026.

Based on the source of the sample taken for performing the diagnostic test, the market is segmented into three categories, viz., blood, tissue and others. Among these segment, blood accounted for the largest revenue generation in 2019 and is expected to grow at a strong double digit CAGR from 2019 to 2026. The blood-based tests provide accurate results when compare to tissue and other source and its less painful for collection from the individual compare to tissue and other source such as cerebrospinal fluid, bone marrow aspirate sample. Also, blood as a sample source can be used for early diagnosis before the occurrence of symptoms.

The cancer diagnostics by the application are classified into cancer type and cancer care segment. The market based on cancer type is further segmented into lung, breast, colorectal, prostate, ovarian, liver and other cancers. The largest revenue was generated by colorectal cancer in 2019 and is expected to grow at a strong double digit CAGR from 2019 to 2026. The cancer care segment is further classified into diagnosis, early screening, companion diagnostics, prognosis and monitoring. Among which, diagnosis accounted for the largest revenue in 2019 whereas, companion diagnostics segment is expected to grow at a strong double digit CAGR from 2019 to 2026.

The cancer diagnostics end-user market is segmented into hospitals, clinical/centralized laboratories, and other end-users such as biopharma, academics and research. Clinical/centralized laboratories segment accounted for the largest revenue in 2019 owing to the access of advanced and novel technologies for the diagnosis and also the availability of skilled professionals with more capital investments as compared with hospitals. Hospitals segment is expected to grow at a high single digit CAGR from 2019 to 2026.

Geographical wise, North America region commanded the largest revenue in 2019, owing to the high demand for early detection, treatment and prevention of cancer with advanced technology due to larger outbreaks of cancer associated with the lifestyle. However, the Asia-Pacific region is expected to grow at a strong double digit CAGR from 2019 to 2026 owing to higher incidence of cancer cases compare to other regions and also increasing awareness programmes on the need for screening and prevention of cancer at early stages.

The cancer diagnostics global market is a competitive market and all the existing players in this market are involved in developing new and advanced techniques for diagnosis to maintain their market shares and also acquiring companies for product expansion and technological innovations.

Some of the key players in cancer diagnostics global market are Abbott Laboratories (U.S.), F.Hoffmann-LA Roche AG (Switzerland), Qiagen (Netherlands), Exact Sciences Corporation (U.S.), Agilent Technologies (U.S.), Danaher Corporation (U.S.), Hologic, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Siemens Healthineers (Germany), and Guardant Health (U.S.).

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITY
        • 3.3.1.1     RISING INCIDENCE OF CANCER AND OLD AGE POPULATION
        • 3.3.1.2     INCREASE IN TECHNOLOGICAL ADVANCEMENT IN CANCER DIAGNOSTICS
        • 3.3.1.3     INCREASE IN HEALTHCARE EXPENDITURE
        • 3.3.1.4     INFRASTRUCTURE AND INVESTMENTS BY GOVERNMENT AND PRIVATE COMPANIES
        • 3.3.1.5     EMERGING MARKETS AND INCREASING AWARENESS OF VARIOUS CANCERS
        • 3.3.1.6     PERSONALIZED MEDICINE
        • 3.3.1.7     MANDATORY EARLY SCREENING
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     HIGH COST OF ADVANCED TECHNOLOGIES
        • 3.3.2.2     LACK OF SKILLED PROFESSIONALS HAMPERING THE GROWTH OF CANCER DIAGNOSTICS MARKET
        • 3.3.2.3     PRODUCT RECALL DUE TO MANUFACTURING AND QUALITY ISSUES
        • 3.3.2.4     STRINGENT REGULATIONS
        • 3.3.2.5     LACK OF REIMBURSEMENT
    • 3.4     MARKET SHARE ANALYSIS
      • 3.4.1     CANCER DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
    • 3.5     REGULATORY AFFAIRS
      • 3.5.1     U.S.
      • 3.5.2     EUROPE
      • 3.5.3     CHINA
      • 3.5.4     INDIA
      • 3.5.5     JAPAN
      • 3.5.6     AUSTRALIA
      • 3.5.7     SOUTH KOREA
    • 3.6     REIMBURSEMENT SCENARIO
    • 3.7     CLINICAL TRIALS
      • 3.7.1     CTDNA CLINICALTRIALS
      • 3.7.2     CFDNA CLINICALTRIALS
      • 3.7.3     CIRCULATING TUMOR CELLS
      • 3.7.4     COMPANION DIAGNOSTICS
      • 3.7.5     IMMUNOASSAYS
    • 3.8     PORTER’S FIVE FORCE ANALYSIS
      • 3.8.1     THREAT OF NEW ENTRANTS
      • 3.8.2     THREAT OF SUBSTITUTES
      • 3.8.3     COMPETITIVE RIVALRY
      • 3.8.4     BARGAINING POWER OF SUPPLIERS
      • 3.8.5     BARGAINING POWER OF BUYERS
  • 4     CANCER DIAGNOSTICS PENETRATION AND TOTAL ADDRESSABLE MARKET (TAM)
    • 4.1     RESEARCH METHODOLOGY
    • 4.2     FORECAST METHODOLOGY
    • 4.3     NORTH AMERICA CANCER DIAGNOSIS ADDRESSABLE MARKET
      • 4.3.1     U.S. COLORECTAL CANCER DIAGNOSTICS MARKET PENETRATION AND TOTAL ADDRESSABLE MARKET (TAM)
        • 4.3.1.1     EARLY SCREENING:
        • 4.3.1.2     U.S. COLORECTAL CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
      • 4.3.2     U.S. BREAST CANCER DIAGNOSTICS TOTAL ADDRESSABLE MARKET (TAM)
        • 4.3.2.1     EARLY SCREENING
        • 4.3.2.2     U.S. BREAST CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
      • 4.3.3     U.S. PROSTATE CANCER DIAGNOSTICS TOTAL ADDRESSABLE MARKET (TAM)
        • 4.3.3.1     EARLY SCREENING:
        • 4.3.3.2     U.S. PROSTATE CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
      • 4.3.4     U.S. LUNG CANCER DIAGNOSTICS TOTAL ADDRESSABLE MARKET (TAM)
        • 4.3.4.1     EARLY SCREENING:
        • 4.3.4.2     U.S. LUNG CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
      • 4.3.5     U.S. OTHER CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
      • 4.3.6     REST OF N.A. CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
    • 4.4     EUROPE CANCER DIAGNOSIS ADDRESSABLE MARKET
      • 4.4.1     EUROPE CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
    • 4.5     APAC CANCER DIAGNOSIS ADDRESSABLE MARKET
      • 4.5.1     APAC CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
    • 4.6     ROW CANCER DIAGNOSIS ADDRESSABLE MARKET
      • 4.6.1     ROW CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
    • 4.7     CANCER CARE GLOBAL ADDRESSABLE MARKET
      • 4.7.1     EARLY SCREENING GLOBAL TOTAL ADDRESSABLE MARKETBY CANCER TYPE AND BY REGION
      • 4.7.2     PROGNOSIS MONITORING GLOBAL TOTAL ADDRESSABLE MARKET BY REGION
      • 4.7.3     COMPANION DIAGNOSTICS GLOBAL TOTAL ADDRESSABLE MARKET BY REGION
      • 4.7.4     RECURRENCE MONITORING GLOBAL TOTAL ADDRESSABLE MARKET BY REGION
  • 5     CANCER DIANOSTICS GLOBAL MARKET, BY TECHNOLOGY
    • 5.1     INTRODUCTION
    • 5.2     IMMUNOASSAYS
      • 5.2.1     IMMUNOHISTOCHEMISTRY (IHC)
      • 5.2.2     ENZYME LINKED IMMUNO SORBENT ASSAY (ELISA)
      • 5.3.3     OTHER IMMUNOASSAYS
    • 5.4     MOLECULAR BASED ASSAYS
      • 5.4.1     IN-SITU HYBRIDIZATION
      • 5.4.2     POLYMERASE CHAIN REACTION (PCR)
      • 5.4.3     MICROARRAY
      • 5.4.4     SEQUENCING
    • 5.5     OTHERS
  • 6     CANCER DIAGNOSTICS GLOBAL MARKET, BY SAMPLE SOURCE
    • 6.1     INTRODUCTION
    • 6.2     BLOOD
    • 6.3     TISSUE
    • 6.4     OTHERS
  • 7     CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET, BY CANCER TYPE
    • 7.1     INTRODUCTION
    • 7.2     CANCER TYPES
      • 7.2.1     LUNG CANCER
      • 7.2.2     BREAST CANCER
      • 7.2.3     COLORECTAL CANCER
      • 7.2.4     PROSTATE CANCER
      • 7.2.5     LIVER CANCER
      • 7.2.6     OVARIAN CANCER
      • 7.2.7     OTHERS
  • 8     CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET, BY CANCER CARE
    • 8.1     INTRODUCTION
    • 8.2     DIAGNOSIS
    • 8.3     EARLY SCREENING
    • 8.4     COMPANION DIAGNOSIS
    • 8.5     PROGNOSIS
    • 8.6     RECURRENCE MONITORING
  • 9     CANCER DIAGNOSTICS GLOBAL MARKET, BY END-USERS
    • 9.1     INTRODUCTION
    • 9.2     HOSPITALS
    • 9.3     CLINICAL/CENTRALIZED LABORATORIES
    • 9.4     OTHERS
  • 10     CANCER DIAGNOSTICS GLOBAL MARKET BY REGION
    • 10.1     INTRODUCTION
    • 10.2     NORTH AMERICA
      • 10.2.1     U.S.
      • 10.2.2     REST OF NORTH AMERICA
    • 10.3     EUROPE
      • 10.3.1     GERMANY
      • 10.3.2     FRANCE
      • 10.3.3     UNITED KINGDOM
      • 10.3.4     REST OF EUROPE
    • 10.4     ASIA-PACIFIC
      • 10.4.1     JAPAN
      • 10.4.2     CHINA
      • 10.4.3     INDIA
      • 10.4.4     REST OF ASIA-PACIFIC
    • 10.5     REST OF THE WORLD
      • 10.5.1     BRAZIL
      • 10.5.2     REST OF LATIN AMERICA
      • 10.5.3     MIDDLE EAST AND OTHER COUNTRIES
  • 11     COMPETITIVE LANDSCAPE
    • 11.1     INTRODUCTION
    • 11.2     APPROVALS
    • 11.3     COLLABORATION
    • 11.4     NEW PRODUCT LAUNCHES
    • 11.5     ACQUSTIONS
    • 11.6     OTHERS
  • 12     MAJOR COMPANIES
    • 12.1     ABBOTT LABORATORIES
      • 12.1.1     OVERVIEW
      • 12.1.2     FINANCIALS
      • 12.1.3     PRODUCT PORTFOLIO
      • 12.1.4     KEY DEVELOPMENTS
      • 12.1.5     BUSINESS STRATEGY
      • 12.1.6     SWOT ANALYSIS
    • 12.2     AGILENT TECHNOLOGIES, INC
      • 12.2.1     OVERVIEW
      • 12.2.2     FINANCIALS
      • 12.2.3     PRODUCT PORTFOLIO
      • 12.2.4     KEY DEVELOPMENTS
      • 12.2.5     BUSINESS STRATEGY
      • 12.2.6     SWOT ANALYSIS
    • 12.3     DANAHER CORPORATION
      • 12.3.1     OVERVIEW
      • 12.3.2     FINANCIALS
      • 12.3.3     PRODUCT PORTFOLIO
      • 12.3.4     KEY DEVELOPMENTS
      • 12.3.5     BUSINESS STRATEGY
      • 12.3.6     SWOT ANALYSIS
    • 12.4     EXACT SCIENCES CORPORATION
      • 12.4.1     OVERVIEW
      • 12.4.2     FINANCIALS
      • 12.4.3     PRODUCT PORTFOLIO
      • 12.4.4     KEY DEVELOPMENTS
      • 12.4.5     BUSINESS STRATEGY
      • 12.4.6     SWOT ANALYSIS
    • 12.5     GUARDANT HEALTH, INC.
      • 12.5.1     OVERVIEW
      • 12.5.2     FINANCIALS
      • 12.5.3     PRODUCT PORTFOLIO
      • 12.5.4     KEY DEVELOPMENTS
      • 12.5.5     BUSINESS STRATEGY
      • 12.5.6     SWOT ANALYSIS
    • 12.6     HOLOGIC, INC.
      • 12.6.1     OVERVIEW
      • 12.6.2     FINANCIALS
      • 12.6.3     PRODUCT PORTFOLIO
      • 12.6.4     KEY DEVELOPMENTS
      • 12.6.5     BUSINESS STRATEGY
      • 12.6.6     SWOT ANALYSIS
    • 12.7     MYRIAD GENETICS, INC.
      • 12.7.1     OVERVIEW
      • 12.7.2     FINANCIALS
      • 12.7.3     PRODUCT PORTFOLIO
      • 12.7.4     KEY DEVELOPMENTS
      • 12.7.5     BUSINESS STRATEGY
      • 12.7.6     SWOT ANALYSIS
    • 12.8     QIAGEN N.V.
      • 12.8.1     OVERVIEW
      • 12.8.2     FINANCIALS
      • 12.8.3     PRODUCT PORTFOLIO
      • 12.8.4     KEY DEVELOPMENTS
      • 12.8.5     BUSINESS STRATEGY
      • 12.8.6     SWOT ANALYSIS
    • 12.9     F. HOFFMANN-LA ROCHE LTD.
      • 12.9.1     OVERVIEW
      • 12.9.2     FINANCIALS
      • 12.9.3     PRODUCT PORTFOLIO
      • 12.9.4     KEY DEVELOPMENTS
      • 12.9.5     BUSINESS STRATEGY
      • 12.9.6     SWOT ANALYSIS
    • 12.10     SIEMENS HEALTHINEERS
      • 12.10.1     OVERVIEW
      • 12.10.2     FINANCIALS
      • 12.10.3     PRODUCT PORTFOLIO
      • 12.10.4     KEY DEVELOPMENTS
      • 12.10.5     BUSINESS STRATEGY
      • 12.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     CANCER DIANGOSTICS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 2     EARLY SCREENING GLOBAL TOTAL ADDRESSABLE MARKET, BY CANCER TYPE VS REGION (2019) ($MN)
      • TABLE 3     CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 4     IMMUNOASSAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 5     IMMUNOASSAYS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 6     IMMUNOHISTOCHEMISTRY (IHC) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 7     ENZYME LINKED IMMUNO SORBENT ASSAY (ELISA) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 8     OTHER IMMUNOASSAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 9     MOLECULAR BASED ASSAYS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 10     MOLECULAR BASED ASSAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 11     IN-SITU HYBRIDIZATION (ISH) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 12     POLYMERASE CHAIN REACTION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 13     MICROARRAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 14     SEQUENCING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 15     OTHERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 16     CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
      • TABLE 17     BLOOD SAMPLE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 18     TISSUE SAMPLE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 19     OTHER SAMPLE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 20     CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
      • TABLE 21     LUNG CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 22     BREAST CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 23     COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 24     PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 25     LIVER CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 26     OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 27     OTHER CANCERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 28     CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
      • TABLE 29     DIAGNOSIS GLOBAL MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 30     EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 31     COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 32     PROGNOSIS MONITORING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 33     RECURRENCE MONITORING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 34     CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS (2018-2026) ($MN)
      • TABLE 35     HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 36     CLINICAL/CENTRALIZED LABORATORIES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 37     OTHERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 38     CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 39     NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 40     NORTH AMERICA IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 41     NORTH AMERICA MOLECULAR BASED ASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 42     NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
      • TABLE 43     NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
      • TABLE 44     NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
      • TABLE 45     NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN)
      • TABLE 46     NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
      • TABLE 47     EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 48     EUROPE IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 49     EUROPE MOLECULAR BASED ASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 50     EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
      • TABLE 51     EUROPE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
      • TABLE 52     EUROPE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
      • TABLE 53     EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN)
      • TABLE 54     EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
      • TABLE 55     ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 56     ASIA-PACIFIC IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 57     ASIA-PACIFIC MOLECULAR BASED ASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 58     ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
      • TABLE 59     ASIA-PACIFIC CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
      • TABLE 60     ASIA-PACIFIC CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
      • TABLE 61     ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN)
      • TABLE 62     ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
      • TABLE 63     REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 64     REST OF THE WORLD IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 65     REST OF THE WORLD MOLECULAR BASED ASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 66     REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
      • TABLE 67     REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
      • TABLE 68     REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
      • TABLE 69     REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN)
      • TABLE 70     REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
      • TABLE 71     APPROVALS (2018-2020)
      • TABLE 72     COLLABORATIONS (2018-2020)
      • TABLE 73     NEW PRODUCT LAUNCH (2018-2020)
      • TABLE 74     ACQUISITIONS (2016-2018)
      • TABLE 75     OTHERS (2018-2020)
      • TABLE 76     ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 77     ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
      • TABLE 78     ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($MN)
      • TABLE 79     AGILENT TECHNOLOGIES, INC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 80     AGILENT TECHNOLOGIES, INC: TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
      • TABLE 81     DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 82     DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 83     DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 84     EXACT SCIENCES CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 85     EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY SEGMENT (2017-2019) ($MN)
      • TABLE 86     EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($MN)
      • TABLE 87     GUARDANT HEALTH, INC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 88     GUARDANT HEALTH, INC: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 89     GUARDANT HEALTH, INC: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 90     HOLOGIC, INC. : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 91     HOLOGIC, INC.: TOTAL REVENUE, BY PRODUCT SEGMENT, (2017-2019) ($MN)
      • TABLE 92     HOLOGIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 93     MYRIAD GENETICS, INC : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q2) ($MN)
      • TABLE 94     MYRIAD GENETICS: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q2) ($MN)
      • TABLE 95     MYRIAD GENETICS:DIAGNOSTICS AND OTHERS BY PRODUCT SEGMENT, (2017-2019) (Q2) ($MN)
      • TABLE 96     QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 97     QIAGEN N.V.: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 98     QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 99     F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 100     F. HOFFMANN-LA ROCHE LTD.: TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q3) ($MN)
      • TABLE 101     F. HOFFMANN-LA ROCHE LTD.: TOTAL REVENUE, BY DIAGNOSTICS SUB-SEGMENTS, (2017-2019) (Q3) ($MN)
      • TABLE 102     F. HOFFMANN-LA ROCHE LTD.: TOTAL DIAGNOSTIC REVENUE, BY REGIONS, (2017-2019) (Q3) ($MN)
      • TABLE 103     SIEMENS HEALTHINEERS : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 104     SIEMENS HEALTHINEERS: TOTAL REVENUE, BY SEGMENT (2017-2019) ($MN)
      • TABLE 105     SIEMENS HEALTHINEERS: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($MN)

      LIST OF FIGURES

      • FIGURE 1     CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: CANCER DIAGNOSTICS GLOBAL MARKET
      • FIGURE 3     CANCER DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     CANCER DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     CANCER DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     CANCER DIAGNOSTICS GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     CANCER DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS (2019) (%)
      • FIGURE 9     CANCER DIAGNOTICS GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 10     U.S. COLORECTAL CANCER EARLY SCREENING PENETRATION AND TOTAL ADDRESSABLE MARKET (%) ($ MN)
      • FIGURE 11     U.S. COLORECTAL CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TAM ($MN)
      • FIGURE 12     U.S. COLORECTAL CANCER EARLY SCREENING MARKET SHARE, BY PLAYERS (%)
      • FIGURE 13     U.S. BREAST CANCER EARLY SCREENING TOTAL ADDRESSABLE MARKET ($ MN)
      • FIGURE 14     U.S. BREAST CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
      • FIGURE 15     U.S. PROSTATE CANCER EARLY SCREENING TOTAL ADDRESSABLE MARKET ($ MN)
      • FIGURE 16     U.S. PROSTATE CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
      • FIGURE 17     U.S. LUNG CANCER EARLY SCREENING TOTAL ADDRESSABLE MARKET ($ MN)
      • FIGURE 18     U.S. LUNG CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
      • FIGURE 19     U.S. OTHER CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
      • FIGURE 20     REST OF N.A. CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
      • FIGURE 21     EUROPE CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
      • FIGURE 22     APAC CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
      • FIGURE 23     ROW CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
      • FIGURE 24     COLORECTAL CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN)
      • FIGURE 25     PROSTATE CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN)
      • FIGURE 26     BREAST CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN)
      • FIGURE 27     LUNG CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN)
      • FIGURE 28     PROGNOSIS MONITORING GLOBAL TAM, BY REGION, 2019 ($MN)
      • FIGURE 29     COMPANION DIAGNOSTICS GLOBAL TAM, BY REGION, 2019 ($MN)
      • FIGURE 30     RECURRENCE MONITORING GLOBAL TAM, BY REGION, 2019 ($MN)
      • FIGURE 31     CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 32     IMMUNOASSAY GLOBAL MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 33     MOLECULAR BASED ASSAYS GLOBAL MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 34     CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
      • FIGURE 35     CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET SHARE, BY CANCER TYPE (2019 VS 2026) (%)
      • FIGURE 36     GLOBAL CANCER PREVALENCE AND INCIDENCE RATE BY TYPE (2019) (%)
      • FIGURE 37     CANCER DIAGNOSTICS APPLICAION GLOBAL MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
      • FIGURE 38     CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY END-USERS (2019 VS 2026) (%)
      • FIGURE 39     CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • FIGURE 40     CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION, MARKET REVENUE BY COUNTRY (2019) (%) ($MN)
      • FIGURE 41     NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 42     NORTH AMERICA IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 43     NORTH AMERICA MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 44     NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
      • FIGURE 45     NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER TYPE (2019 VS 2026) (%)
      • FIGURE 46     NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
      • FIGURE 47     NORTH AMERICA CANCER DIAGNOSTICS L MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 48     NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
      • FIGURE 49     U.S. CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
      • FIGURE 50     U.S. CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
      • FIGURE 51     U.S. CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
      • FIGURE 52     REST OF NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
      • FIGURE 53     REST OF NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
      • FIGURE 54     REST OF NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
      • FIGURE 55     EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 56     EUROPE IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 57     EUROPE MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 58     EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
      • FIGURE 59     EUROPE CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
      • FIGURE 60     EUROPE CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
      • FIGURE 61     EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 62     EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
      • FIGURE 63     GERMANY CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
      • FIGURE 64     GERMANY CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
      • FIGURE 65     GERMANY CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
      • FIGURE 66     FRANCE CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
      • FIGURE 67     FRANCE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
      • FIGURE 68     FRANCE CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
      • FIGURE 69     U.K. CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
      • FIGURE 70     U.K. CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
      • FIGURE 71     U.K. CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
      • FIGURE 72     REST OF EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
      • FIGURE 73     REST OF EUROPE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
      • FIGURE 74     REST OF EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
      • FIGURE 75     APAC CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 76     APAC IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 77     APAC MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 78     APAC CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
      • FIGURE 79     APAC CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
      • FIGURE 80     APAC CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
      • FIGURE 81     APAC CANCER DIAGNOSTICS MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 82     APAC CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
      • FIGURE 83     JAPAN CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
      • FIGURE 84     JAPAN CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
      • FIGURE 85     JAPAN CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
      • FIGURE 86     CHINA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
      • FIGURE 87     CHINA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
      • FIGURE 88     CHINA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
      • FIGURE 89     INDIA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
      • FIGURE 90     INDIA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
      • FIGURE 91     INDIA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
      • FIGURE 92     REST OF APAC CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
      • FIGURE 93     REST OF APACCANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
      • FIGURE 94     REST OF APAC CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
      • FIGURE 95     REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 96     REST OF THE WORLD IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 97     REST OF THE WORLD MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
      • FIGURE 98     REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
      • FIGURE 99     REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
      • FIGURE 100     REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
      • FIGURE 101     REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 102     REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
      • FIGURE 103     BRAZIL CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
      • FIGURE 104     BRAZIL CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
      • FIGURE 105     BRAZIL CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
      • FIGURE 106     REST OF LATIN AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
      • FIGURE 107     REST OF LATIN AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
      • FIGURE 108     REST OF LATIN AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
      • FIGURE 109     MIDDLE EAST AND OTHERS CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
      • FIGURE 110     MIDDLE EAST AND OTHERS CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
      • FIGURE 111     MIDDLE EAST AND OTHERS CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
      • FIGURE 112     KEY GROWTH STRATEGIES, (2018 – 2020)
      • FIGURE 113     SWOT: ABBOTT LABORATORIES
      • FIGURE 114     SWOT: AGILENT TECHNOLOGIES
      • FIGURE 115     SWOT: DANAHER CORPORATION
      • FIGURE 116     SWOT: EXACT SCIENCES
      • FIGURE 117     SWOT: GUARDANT HEALTH
      • FIGURE 118     SWOT: HOLOGIC, INC
      • FIGURE 119     SW0T: MYRIAD GENETICS
      • FIGURE 120     SW0T: QIAGEN N.V.
      • FIGURE 121     SW0T: ROCHE
      • FIGURE 122     SW0T: SIEMENS HEALTHINEERS

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ABBOTT LABORATORIES
      • 2     ACCURAGEN, INC
      • 3     ACRANNOLIFE GENOMICS
      • 4     ADAPTIVE BIOTECHNOLOGIES
      • 5     AGENA BIOSCIENCES
      • 6     AGENDIA
      • 7     AGILENT TECHNOLOGIES
      • 8     ANGLE PLC
      • 9     ANGSANA MOLECULAR & DIAGNOSTIC LABORATORY (AMDL) PTE LTD
      • 10     ARUP LABORATORIES
      • 11     AVANT DIAGNOSTICS
      • 12     BARD1 LIFE SCIENCES LTD
      • 13     BGI
      • 14     BIOAFFINITY TECHNOLOGIES
      • 15     BIOARRAY SL
      • 16     BIOCARTIS
      • 17     BIOCEPT
      • 18     BIODESIX, INC
      • 19     BIOGENEX
      • 20     BIOMARK DIAGNOSTICS, INC
      • 21     BIOMÉRIEUX
      • 22     BIO-RAD LABORATORIES
      • 23     BIORELIANCE
      • 24     BIO-TECHNE CORPORATION
      • 25     BIOTHERANOSTICS
      • 26     BIOTYPE DIAGNOSTIC GMBH
      • 27     BIOVICA
      • 28     BOSTER BIOLOGICAL TECHNOLOGY
      • 29     CANCER GENETICS, INC
      • 30     CANCER TREATMENT OPTIONS AND MANAGEMENT INC
      • 31     CARIS LIFESCIENCES
      • 32     CASTLE BIOSCIENCES
      • 33     CELL MAX LIFE
      • 34     CELL SIGNALING TECHNOLOGY
      • 35     CHRONIX BIOMEDICAL
      • 36     CIRCULOGENE
      • 37     CLEVELAND DIAGNOSTICS
      • 38     CLINICAL GENOMICS TECHNOLOGIES PTY LTD
      • 39     CONCILE GMBH
      • 40     CONTEXTUAL GENOMICS
      • 41     CREATIVE DIAGNOSTICS
      • 42     DAKO NORTH AMERICA, INC
      • 43     DANAHER CORPORATION
      • 44     DATAR CANCER DIAGNOSTICS
      • 45     DELTAGENE
      • 46     DIACARTA
      • 47     DIASORIN
      • 48     DIASOURCE IMMUNOASSAYS SA
      • 49     ELABSCIENCE
      • 50     ENTERIX, INC
      • 51     ENZO LIFESCIENCES
      • 52     EPIGENOMICS GMBH
      • 53     EPPENDORF AG
      • 54     EXACT SCIENCES CORPORATION
      • 55     EXOSOME DIAGNOSTICS, INC
      • 56     EXOSOMICS S.P.A
      • 57     F. HOFFMANN-LA ROCHE LTD
      • 58     FARCAST BIOSCIENCES, INC
      • 59     FOUNDATION MEDICINE
      • 60     GENE EDITING INSTITUTE AT CHRISTIANA CARE HEALTH SYSTEM
      • 61     GENERAL BIOLOGICALS CORPORATION
      • 62     GENOMA GROUP
      • 63     GENOMEME
      • 64     GENOMIC DIAGNOSTICS
      • 65     GENOMIC VISION
      • 66     GENOPTIX
      • 67     GUARDANT HEALTH
      • 68     HALIODX
      • 69     HEMOSURE, INC
      • 70     HOLOGIC,INC
      • 71     ICON, PLC
      • 72     IKONISYS
      • 73     IMMUNOSTICS
      • 74     INDIVUMED GMBH
      • 75     INIVATA
      • 76     INOVA DIAGNOSTICS
      • 77     INTEGRATED DIAGNOSTICS, INC
      • 78     INVIVOSCRIBE TECHNOLOGIES, INC.
      • 79     JOHNSON & JOHNSON (JANSSEN DIAGNOSTICS)
      • 80     LABCORP
      • 81     LCM GENECT SRL
      • 82     LIFESPAN BIOSCIENCES (LS BIO)
      • 83     LIQUID BIOTECH USA
      • 84     LUMINEX CORPORATION
      • 85     LUNGLIFE AI
      • 86     LXREPAIR
      • 87     MAPMYGENOME INDIA LTD
      • 88     MDXHEALTH
      • 89     MEDGENOME LABS LTD.
      • 90     MENARINI SILICON BIOSYSTEMS
      • 91     MERCK KGAA
      • 92     METAMARK GENETICS, INC
      • 93     MICHELSON DIAGNOSTICS
      • 94     MIRDETECT GMBH
      • 95     MIRXES PTE LTD
      • 96     MYBIOSOURCE
      • 97     MYRIAD GENETICS
      • 98     NANOSTRING TECHNOLOGIES
      • 99     NATERA
      • 100     NEO NEW ONCOLOGY GMBH
      • 101     NEOGENOMICS LABORATORIES
      • 102     NOVIGENIX
      • 103     ONCGNOSTICS GMBH
      • 104     ONCIMMUNE
      • 105     ONCOCYTE CORPORATION
      • 106     ONCODIAG
      • 107     OPKO HEALTH INC
      • 108     OXFORD CANCER BIOMARKER
      • 109     OXFORD GENE TECHNOLOGY
      • 110     PANAGENE
      • 111     PANGAEA ONCOLOGY
      • 112     PATHWAY GENOMICS
      • 113     PERKINELMER INC.
      • 114     PERSONAL GENOME DIAGNOSTICS, INC
      • 115     PRECIPIODX
      • 116     PREDICINE, INC
      • 117     QIAGEN N.V
      • 118     QUIDEL CORPORATION, U.S.
      • 119     R&D SYSTEMS, INC,
      • 120     RESOLUTION BIOSCIENCE
      • 121     RHYTHM BIOSCIENCES
      • 122     RIBOMED
      • 123     SANSURE BIOTECH
      • 124     SIEMENS HEALTHINEERS
      • 125     SIENNA CANCER DIAGNOSTICS
      • 126     SINO BIOLOGICAL INC.
      • 127     SPHINGOTEC GMBH
      • 128     STAGE ZERO LIFE SCIENCES
      • 129     SYNLAB INTERNATIONAL GMBH
      • 130     SYSMEX CORPORATION
      • 131     THERADIAG
      • 132     THERMOFISHER SCIENTIFIC
      • 133     THRIVE EARLIER DETECTION
      • 134     TOSOH BIOSCIENCES
      • 135     VIENNALAB DIAGNOSTICS GMBH
      • 136     VIGILANT BIOSCIENCES 
      • 137     VITADX
      • 138     VOLITIONRX